Quest Diagnostics Prices $500 Million of Senior Notes

Quest Diagnostics (NYSE: DGX) priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration.

Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration. The company expects net proceeds at closing on May 6, 2026, to be used for general corporate purposes, which may include repaying indebtedness.

The announcement notes the company may repay its $500 million aggregate principal amount of 3.45% senior notes maturing on June 1, 2026. The offering will be made via a prospectus supplement and base prospectus; bookrunners include Goldman Sachs, J.P. Morgan, and Mizuho.

Positive

• Raises $500 million in long-term financing maturing 2036
• Proceeds available for repayment of near-term maturing debt
• Maintains corporate liquidity and financing flexibility

Negative

• New notes carry a 5.000% coupon versus 3.45% on maturing notes
• Higher interest cost on refinanced debt could increase financing expense

Argus Apr 28 session

-0.80% close to close Open Argus

Details

News Market Reaction – DGX

In the Apr 28 session, DGX declined 0.80%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details the pricing of $500 million of 5.000% senior notes due 2036, likely under ...

Analysis

This announcement details the pricing of $500 million of 5.000% senior notes due 2036, likely under Quest’s effective S-3ASR shelf, with proceeds earmarked for general corporate purposes including possible repayment of $500 million 3.45% notes maturing June 1, 2026. It follows strong Q1 2026 results and raised guidance. Investors may watch future debt issuance activity, upcoming maturities, and how operating cash flow and earnings support ongoing interest and principal obligations.

Key Figures

New senior notes size: $500 million Coupon rate: 5.000% Maturity year: 2036 +4 more

New senior notes size

$500 million

Aggregate principal amount of 5.000% senior notes due 2036

Coupon rate

5.000%

Interest rate on new senior notes due 2036

Maturity year

2036

Maturity of newly issued senior notes

Closing date

May 6, 2026

Expected closing for receipt of net proceeds

Notes to be repaid

$500 million

Aggregate principal of 3.45% Senior Notes maturing June 1, 2026

Existing coupon

3.45%

Coupon on Senior Notes maturing June 1, 2026

Existing maturity date

June 1, 2026

Maturity of 3.45% Senior Notes referenced for potential repayment

Historical Context

5 past events · Latest: Apr 21

5 events

1. Apr 21

   Earnings results

   24h Move

   +4.5%

   Strong Q1 2026 results and raised full‑year revenue and EPS guidance.

2. Apr 16

   Research collaboration

   24h Move

   +0.0%

   Multi‑year MRD ctDNA collaboration with City of Hope across multiple cancers.

3. Mar 19

   Earnings date notice

   24h Move

   -0.6%

   Announcement of Q1 2026 earnings release date and conference call details.

4. Mar 12

   Board change

   24h Move

   -0.6%

   Election of former large‑cap healthcare CEO Timothy Wentworth to board.

5. Mar 02

   Product launch

   24h Move

   -0.8%

   Launch of Quest AI Companion in MyQuest using Google’s Gemini models.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

senior notes, shelf registration statement, prospectus supplement, base prospectus

4 terms

senior notes financial

"announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036"

Senior notes are a type of loan that a company borrows from investors, promising to pay it back with interest. They are called "senior" because in case the company faces financial trouble, these lenders are paid back before others. This makes senior notes safer for investors compared to other types of loans or bonds.

shelf registration statement regulatory

"5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"This offering may be made only by means of a prospectus supplement and accompanying base prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

base prospectus regulatory

"may be made only by means of a prospectus supplement and accompanying base prospectus"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement. 

Quest Diagnostics expects to receive the net offering proceeds upon closing on May 6, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay with the net proceeds of this offering includes its $500 million aggregate principal amount of 3.45% Senior Notes which will mature on June 1, 2026.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning this offering may be obtained by calling Goldman Sachs & Co. LLC, toll free at 1 (866) 471-2526, J.P. Morgan Securities LLC, collect at 1-212-834-4533 or Mizuho Securities USA LLC, toll free at 1-866-271-7403.

About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives.

Forward Looking Statements 
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs, including with regard to the consummation of the offering of the Notes, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-prices-500-million-of-senior-notes-302754723.html

SOURCE Quest Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Quest Diagnostics (DGX) announce about the $500 million senior notes?

Quest Diagnostics priced $500 million of 5.000% senior notes due 2036. According to the company, net proceeds are expected at closing on May 6, 2026 and may be used for general corporate purposes including debt repayment.

When will Quest Diagnostics (DGX) receive proceeds from the 5.000% senior notes offering?

Quest Diagnostics expects to receive net proceeds upon closing on May 6, 2026. According to the company, closing remains subject to customary conditions and the offering will be effected by prospectus supplement and base prospectus.

Will Quest Diagnostics (DGX) use the offering to repay existing debt maturing in June 2026?

The company said the net proceeds may repay indebtedness, including $500 million of 3.45% senior notes maturing June 1, 2026. According to the company, repayment is one possible use of proceeds, not a guaranteed use.

How does the coupon on the new DGX notes compare to the maturing notes?

The new notes carry a 5.000% coupon versus 3.45% on the maturing notes due June 1, 2026. According to the company, this reflects the terms of the new 2036 senior notes priced in the offering.

Who are the bookrunners for Quest Diagnostics (DGX) senior notes offering and where can investors get the prospectus?

Goldman Sachs, J.P. Morgan, and Mizuho are listed as contacts for the offering. According to the company, copies of the prospectus supplement and base prospectus are available by contacting those firms as provided in the announcement.